Mucopolysaccharidosis IIIB (MPS IIIB) (Sanfilippo Syndrome Type B; OMIM 252920) is an autosomal recessive metabolic disorder caused by mutations in the NAGLU gene which encode lysosomal enzyme N-acetyl-glucosaminidase, involved in degradation of complex polysaccharide, heparan sulfate. The disease is characterized by progressive cognitive decline and behavioral difficulties and motor function retardation.
Introduction

Mucopolysaccharidosis
IIIB (MPS IIIB) (Sanfilippo Syndrome Type B; OMIM 252920) is an autosomal recessive metabolic disorder caused by mutations in the NAGLU gene, which encode lysosomal enzyme N-acetyl-glucosaminidase (1) . This enzyme involved in breakdown a subset of glycosaminoglycan compound called heparan sulfate. Its impaired function leads to increased urinary excretion and accumulation of partially degraded component in tissues (2) .
Over 150 different NAGLU mutations have been reported in the Human Gene Mutation Database (HGMD). MPS IIIB is clinically heterogeneous (3) (4) (5) but the clinical course of MPS III can be divided into three phases (6, 7) . In the first phase, which usually starts between 1 and 4 yr of age, delayed cognitive development becomes apparent after an initial normal pre-natal and early post-natal of life.
The second phase of the disease commonly begins around 3-5 yr and can last for 5 to 10 years. This phase is characterized by progressive behavioral difficulties ultimately leading to severe dementia.
Hyperactivity, gradual intelligence decline, sleep disturbance in combination with good muscular strength make difficult to manage the affected child. In the third and final stage, the nature of illness change, behavioral problems come to end slowly and progressive motor retardation with swallowing difficulties and spasticity appear and ultimately patient regress to a vegetative state.
In MPS IIIB, death usually occurs at the end of the second or the beginning of the third decade of life, but survival into the fourth decade has been reported in attenuated form (6) .
In this study, using targeted exome sequencing, we identified novel heterozygote mutations in the NAGLU gene in consanguineous parents of a child who was deceased in her 14 years old where the diagnosis of death was mucopolysaccharidosis. expasy.org/) (14-17).
Materials & Methods
Subjects
Co-segregation study
The co-segregation of the variant with the NAGLU gene was done using Sanger sequencing for the family members and extended family members of the proband in order to confirm the accuracy of detected variant identified by NGS. Genomics (ACMG) guideline (18) .
Results
The affected individual described in this paper was diagnosed with MPS by exact clinical evaluation but did not undergo molecular diagnosis in her lifetime. Her parents were consanguineous, therefore we studied for alteration in 10 known pathogenic genes in MPS in deceased child's mother and then we evaluated the identified variant in proband , s husband and other relatives.
The analytical sensitivity and specificity of NGS kb and encodes a 743 amino acid protein (1, 21) .
More than 150 mutations have been reported in the NAGLU gene to date, the greater number of them are missense but also nonsense and Indels have reduced catalytic activities of the NAGLU protein.
In addition, the interruption in the interaction with other cooperating protein was responsible for the etiology. (26) . In this study, the novel it critically for important intellectual content, analysis, or interpretation of data for the work.
